PE20181317A1 - Aglutinantes de tnf mejorados - Google Patents
Aglutinantes de tnf mejoradosInfo
- Publication number
- PE20181317A1 PE20181317A1 PE2018000766A PE2018000766A PE20181317A1 PE 20181317 A1 PE20181317 A1 PE 20181317A1 PE 2018000766 A PE2018000766 A PE 2018000766A PE 2018000766 A PE2018000766 A PE 2018000766A PE 20181317 A1 PE20181317 A1 PE 20181317A1
- Authority
- PE
- Peru
- Prior art keywords
- tnf
- polypeptides
- compounds
- necrosis factor
- tumor necrosis
- Prior art date
Links
- 239000011230 binding agent Substances 0.000 title abstract 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 3
- 102100040247 Tumor necrosis factor Human genes 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 150000005829 chemical entities Chemical class 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Organic Insulating Materials (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Abstract
La presente invencion se refiere a secuencias de aminoacidos, compuestos y polipeptidos que se unen al factor de necrosis tumoral alfa ("TNF" o "TNF - alfa"). En particular, la presente invencion se refiere a dominios variables unicos de inmunoglobulina de cadena pesada mejorados (tambien denominados aqui como "ISV" o " I SVD") que se unen al factor de necrosis tumoral alfa, asi como a proteinas, polipeptidos y otros constructos, compuestos, moleculas o entidades quimicas que comprenden tales ISVD, colectivamente aglutinantes de TNF
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562254375P | 2015-11-12 | 2015-11-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20181317A1 true PE20181317A1 (es) | 2018-08-14 |
Family
ID=57348648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018000766A PE20181317A1 (es) | 2015-11-12 | 2016-11-14 | Aglutinantes de tnf mejorados |
Country Status (36)
| Country | Link |
|---|---|
| US (2) | US10544211B2 (es) |
| EP (2) | EP3266798A3 (es) |
| JP (2) | JP6962915B2 (es) |
| KR (2) | KR102641194B1 (es) |
| CN (1) | CN108473563B (es) |
| AU (2) | AU2016352943B2 (es) |
| BR (1) | BR112018009714A8 (es) |
| CA (2) | CA3234178A1 (es) |
| CL (1) | CL2018001291A1 (es) |
| CO (1) | CO2018005915A2 (es) |
| CR (1) | CR20180311A (es) |
| CY (1) | CY1120303T1 (es) |
| DK (1) | DK3191511T3 (es) |
| DO (1) | DOP2018000122A (es) |
| EC (1) | ECSP18042569A (es) |
| ES (1) | ES2662418T3 (es) |
| GT (1) | GT201800095A (es) |
| HK (1) | HK1248716A1 (es) |
| HR (1) | HRP20171949T1 (es) |
| HU (1) | HUE035805T2 (es) |
| IL (2) | IL310373A (es) |
| LT (1) | LT3191511T (es) |
| MA (1) | MA41653A (es) |
| MD (1) | MD3191511T2 (es) |
| ME (1) | ME02954B (es) |
| MX (1) | MX2018005992A (es) |
| NO (1) | NO2768984T3 (es) |
| PE (1) | PE20181317A1 (es) |
| PH (1) | PH12018501025A1 (es) |
| PL (1) | PL3191511T3 (es) |
| PT (1) | PT3191511T (es) |
| RS (1) | RS56676B1 (es) |
| SG (1) | SG11201803975SA (es) |
| SI (1) | SI3191511T1 (es) |
| TN (1) | TN2018000159A1 (es) |
| WO (1) | WO2017081320A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| EP2723769B2 (en) | 2011-06-23 | 2022-06-15 | Ablynx NV | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| HUE050007T2 (hu) | 2014-05-16 | 2020-11-30 | Ablynx Nv | Immunglobulin variábilis domének |
| NO2768984T3 (es) * | 2015-11-12 | 2018-06-09 | ||
| GB201522394D0 (en) | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibodies |
| JP2023505492A (ja) | 2019-12-06 | 2023-02-09 | アブリンクス・エヌ・フェー | ＴＮＦαおよびＩＬ－２３を標的化する免疫グロブリン単一可変ドメインを含むポリペプチド |
| EP4069293A1 (en) | 2019-12-06 | 2022-10-12 | Ablynx N.V. | Polypeptides comprising immunoglobulin single variable domains targeting tnfa and ox40l |
| CN112300289B (zh) * | 2019-12-30 | 2022-06-10 | 中国药科大学 | RGD4C融合抗TNFα纳米抗体蛋白、制备方法及其应用 |
| KR20230123497A (ko) * | 2020-12-18 | 2023-08-23 | 아블린쓰 엔.브이. | IL-6 및 TNF-α를 표적화하는 면역글로불린 단일 가변도메인을 포함하는 폴리펩티드 |
| WO2024097571A1 (en) * | 2022-11-04 | 2024-05-10 | St. Jude Children's Research Hospital, Inc. | Nlrp12 and nlrc5 modulators and methods for using the same to modulate diseases |
| WO2024133935A1 (en) | 2022-12-23 | 2024-06-27 | Ablynx Nv | Protein-based conjugation carriers |
| WO2024170756A1 (en) | 2023-02-17 | 2024-08-22 | Ablynx N.V. | Polypeptides binding to the neonatal fc receptor |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2192131A1 (en) | 1992-08-21 | 2010-06-02 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| EP1027439B1 (en) | 1997-10-27 | 2010-03-17 | Bac Ip B.V. | Multivalent antigen-binding proteins |
| BR9907950A (pt) | 1998-02-19 | 2001-12-18 | Xcyte Therapies Inc | Composições e processos para regulagem deativação de linfócitos |
| US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| JP2006520584A (ja) | 2002-11-08 | 2006-09-14 | アブリンクス エン．ヴェー． | 安定化単一ドメイン抗体 |
| CN101412759A (zh) | 2003-01-10 | 2009-04-22 | 埃博灵克斯股份有限公司 | 治疗性多肽,其同源物、其片段及其在调节血小板介导的聚集方面的应用 |
| DK1639011T3 (da) | 2003-06-30 | 2009-02-16 | Domantis Ltd | Pegylerede enkelt-domæne antistoffer (dAb) |
| ES2352697T3 (es) | 2003-11-07 | 2011-02-22 | Ablynx N.V. | Anticuerpos de dominio único de camelidae vhh dirigidos contra el receptor del factor de crecimiento epidérmico y usos de los mismos. |
| CA2583017A1 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease |
| US20090191217A1 (en) | 2004-12-02 | 2009-07-30 | De Wildt Ruud M | Anti-IL-1R1 Single Domain Antibodies And Therapeutic Uses |
| EP2172484A3 (en) * | 2005-05-18 | 2010-05-19 | Ablynx N.V. | Serum albumin binding proteins |
| CN101213214B (zh) | 2005-05-20 | 2014-06-25 | 埃博灵克斯股份有限公司 | 针对冯威勒布兰特因子的单一结构域vhh抗体 |
| DE102005023617A1 (de) * | 2005-05-21 | 2006-11-23 | Aspre Ag | Verfahren zum Mischen von Farben in einem Display |
| US9017662B2 (en) | 2005-08-30 | 2015-04-28 | Actogenix N.V. | Anti-TNF alpha producing lactic acid bacteria for the treatment of chronic enterocolitis |
| EP1957536A2 (en) | 2005-12-01 | 2008-08-20 | Domantis Limited | Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1 |
| TW200736276A (en) | 2005-12-01 | 2007-10-01 | Domantis Ltd | Competitive domain antibody formats that bind interleukin 1 receptor type 1 |
| FR2894741B1 (fr) | 2005-12-08 | 2009-12-04 | Centre Nat Etd Spatiales | Chaine de reception par satellite |
| AU2007209201A1 (en) | 2006-01-24 | 2007-08-02 | Domantis Limited | Fusion proteins that contain natural junctions |
| AU2007285695B2 (en) | 2006-08-18 | 2012-05-24 | Ablynx N.V. | Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling |
| EP2097449A1 (en) | 2006-12-05 | 2009-09-09 | Ablynx N.V. | Peptides capable of binding to serum proteins |
| CA2687903C (en) | 2007-05-24 | 2016-09-13 | Ablynx N.V. | Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders |
| WO2009068625A2 (en) | 2007-11-27 | 2009-06-04 | Ablynx N.V. | Amino acid sequences directed against her2 and polypeptides comprising the same for the treatment of cancers and/or tumors |
| DE102008023620A1 (de) | 2008-05-15 | 2009-11-19 | Mettler-Toledo (Albstadt) Gmbh | Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf |
| EP2285833B1 (en) | 2008-05-16 | 2014-12-17 | Ablynx N.V. | AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME |
| JP2012517818A (ja) * | 2009-02-19 | 2012-08-09 | グラクソ グループ リミテッド | 改善された抗ｔｎｆｒ１ポリペプチド、抗体可変ドメインおよびアンタゴニスト |
| BRPI1013877A2 (pt) | 2009-04-10 | 2017-08-15 | Ablynx Nv | Sequências de aminoácidos melhoradas contra il-6r e polipeptídeos que compreendem os mesmos para o tratamento de doenças e distúrbios relacionados com il-6r |
| WO2010130832A2 (en) | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions |
| JP2012532620A (ja) | 2009-07-16 | 2012-12-20 | グラクソ グループ リミテッド | 改良型抗血清アルブミン結合単一可変ドメイン |
| US9120855B2 (en) | 2010-02-10 | 2015-09-01 | Novartis Ag | Biologic compounds directed against death receptor 5 |
| US20150158948A9 (en) | 2011-03-28 | 2015-06-11 | Francis Descamps | Bispecific anti-cxcr7 immunoglobulin single variable domains |
| HUE047238T2 (hu) | 2011-06-23 | 2020-04-28 | Ablynx Nv | Szérumalbuminhoz kötõdõ fehérjék |
| EP2723769B2 (en) * | 2011-06-23 | 2022-06-15 | Ablynx NV | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| UA118833C2 (uk) * | 2011-08-17 | 2019-03-25 | Ґлаксо Ґруп Лімітед | Одиничний варіабельний домен імуноглобуліну, який зв'язується з tnfr1 |
| WO2014111550A1 (en) | 2013-01-17 | 2014-07-24 | Glaxosmithkline Intellectual Property Development Limited | Modified anti-serum albumin binding proteins |
| HUE050007T2 (hu) * | 2014-05-16 | 2020-11-30 | Ablynx Nv | Immunglobulin variábilis domének |
| NO2768984T3 (es) | 2015-11-12 | 2018-06-09 | ||
| EP3414268A1 (en) * | 2016-02-12 | 2018-12-19 | Ablynx NV | Method for the production of immunoglobulin single variable domains |
-
2012
- 2012-10-19 NO NO12841612A patent/NO2768984T3/no unknown
-
2016
- 2016-11-13 MA MA041653A patent/MA41653A/fr unknown
- 2016-11-14 IL IL310373A patent/IL310373A/en unknown
- 2016-11-14 PL PL16798122T patent/PL3191511T3/pl unknown
- 2016-11-14 PE PE2018000766A patent/PE20181317A1/es unknown
- 2016-11-14 HU HUE16798122A patent/HUE035805T2/en unknown
- 2016-11-14 KR KR1020187016731A patent/KR102641194B1/ko active IP Right Grant
- 2016-11-14 CR CR20180311A patent/CR20180311A/es unknown
- 2016-11-14 AU AU2016352943A patent/AU2016352943B2/en active Active
- 2016-11-14 CA CA3234178A patent/CA3234178A1/en active Pending
- 2016-11-14 CN CN201680076588.6A patent/CN108473563B/zh active Active
- 2016-11-14 DK DK16798122.4T patent/DK3191511T3/en active
- 2016-11-14 ME MEP-2017-291A patent/ME02954B/me unknown
- 2016-11-14 EP EP17184686.8A patent/EP3266798A3/en not_active Withdrawn
- 2016-11-14 CA CA3005085A patent/CA3005085A1/en active Pending
- 2016-11-14 MD MDE20170066T patent/MD3191511T2/ro unknown
- 2016-11-14 SI SI201630013T patent/SI3191511T1/en unknown
- 2016-11-14 PT PT167981224T patent/PT3191511T/pt unknown
- 2016-11-14 JP JP2018524836A patent/JP6962915B2/ja active Active
- 2016-11-14 LT LTEP16798122.4T patent/LT3191511T/lt unknown
- 2016-11-14 MX MX2018005992A patent/MX2018005992A/es unknown
- 2016-11-14 IL IL259269A patent/IL259269B2/en unknown
- 2016-11-14 BR BR112018009714A patent/BR112018009714A8/pt active Search and Examination
- 2016-11-14 TN TNP/2018/000159A patent/TN2018000159A1/en unknown
- 2016-11-14 SG SG11201803975SA patent/SG11201803975SA/en unknown
- 2016-11-14 KR KR1020247005963A patent/KR20240029115A/ko active Application Filing
- 2016-11-14 EP EP16798122.4A patent/EP3191511B1/en active Active
- 2016-11-14 WO PCT/EP2016/077595 patent/WO2017081320A1/en active Application Filing
- 2016-11-14 RS RS20171299A patent/RS56676B1/sr unknown
- 2016-11-14 US US15/501,011 patent/US10544211B2/en active Active
- 2016-11-14 ES ES16798122.4T patent/ES2662418T3/es active Active
-
2017
- 2017-03-13 US US15/456,824 patent/US9745372B2/en active Active
- 2017-12-01 HK HK18108106.4A patent/HK1248716A1/zh unknown
- 2017-12-15 HR HRP20171949TT patent/HRP20171949T1/hr unknown
- 2017-12-19 CY CY20171101330T patent/CY1120303T1/el unknown
-
2018
- 2018-05-11 DO DO2018000122A patent/DOP2018000122A/es unknown
- 2018-05-11 CL CL2018001291A patent/CL2018001291A1/es unknown
- 2018-05-11 GT GT201800095A patent/GT201800095A/es unknown
- 2018-05-15 PH PH12018501025A patent/PH12018501025A1/en unknown
- 2018-06-05 EC ECIEPI201842569A patent/ECSP18042569A/es unknown
- 2018-06-08 CO CONC2018/0005915A patent/CO2018005915A2/es unknown
-
2021
- 2021-10-14 JP JP2021168871A patent/JP7357038B2/ja active Active
-
2023
- 2023-01-10 AU AU2023200113A patent/AU2023200113A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20181317A1 (es) | Aglutinantes de tnf mejorados | |
| MX2023007520A (es) | Aglutinantes de albumina de suero mejorados. | |
| PH12017502129A1 (en) | Antibodies against ox40 and uses thereof | |
| ECSP19011185A (es) | Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a CD3 y CD123 | |
| MX2023005374A (es) | Aglutinantes de albumina serica mejorados. | |
| MX2024008521A (es) | Aglutinantes de albumina serica mejorados. | |
| EA201891121A1 (ru) | Антитела к глюкокортикоид-индуцированному рецептору фактора некроза опухоли (gitr) и их применения | |
| SG10201909716RA (en) | Modified j-chain | |
| PH12019500209A1 (en) | Methods and compositions for gene expression in plants | |
| MX371403B (es) | Moleculas de andamiaje a base de fibronectina estabilizada. | |
| EA201591993A1 (ru) | Лечение склеродермии с применением комбинированной терапии антителами анти-ccl2 и анти-loxl2 | |
| EA201991088A1 (ru) | Связывающие пептиды | |
| AR100744A1 (es) | Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus usos |